1ATTAL M, HAROUSSEAU J L, STOPPA A M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupc Francais du Myclome[J]. N Engl J Med, 1996,335(2) :91-97.
2CHILD J A, MORGAN G J, DAVIES F E, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for muhiple myeloma [J]. N Engl J Med, 2003,348(19) :1875-1883.
3ATTAL M, HAROUSSEAU J L, FACON T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma [J]. N Engl J Med, 2003,349(26) :2495-2502.
4VAN D E VELDE H J, LIU X, CHEN G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma[ J]. Haematologica, 2007, 92(10) :1399-1406.
5BRUNO B, ROTTA M, PATR1ARCA F,et al. A comparison of allografting with autografling for newly diagnosed myeloma [J]. N Engl J Med, 2007,356( 11 ) : 1110-1120.
6RAJKUMAR S V, BLOOD E, YESOLE D, et al. Phase Ⅲ clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newl) diagnosed multiple mveloma :clinical trial coordinated by the Eastern Cooperative Oncology Group [J]. J Clin Oncol, 2006,24 ( 3 ) :431-436.
7PALUMBO A, BRINGHEN S, CARAVITA T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone myeloma: randomised controlled (9513) :825-831. in elderly patients with multiple trial [ J ]. Lancet, 2006, 367
8FACON T, MARY J Y, HULIN C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with muhipte myeloma (IFM 99-06 ): a randomised trial [J]. Lancet, 2007.370(9594):1209-1218.
9WEBER D M,CHEN C, NIESVIZKY R,et al. Lenalidomide plus dexamethasone for relapsed multiple mveloma in North America[J]. N Engl J Med, 2007,357(21):2133-2142.
10DIMOPOULOS M, St:'ENCER A, ATTAL M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [J]. N Engl J Med, 2007,357(21):2123-2132.
二级参考文献8
1Myeloma Trialists' Collaborative Group.Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma:an overview of 6,633 patients from 27randomized trials[J].J Clin Oncol,1998,16(12):3832-3842.
2Clerc D,Fermand J P,Mariette X.Treatment of multiple myeloma[J].Joint Bone Spine,2003,70(3):175-186.
3Turesson I,Abildgaard N,Ahlgren T,et al.Prognostic evaluation in multiple myeloma:an analysis of the impact of new prognostic factors[J].Br J Haematol,1999,106(4):1005-1012.
4Bataille R,Boccadoro M,Klein B,et al.C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system[J].Blood,1992,80 (3):733-737.
5Greipp P R,San Miguel J,Durie B G,et al.International staging system for multiple myeloma[J].J Clin Oncol,2005,23 (15):3412-3420.
6Pruzanski W.Clinical manifestations of multiple myeloma:relation to class and type M component[J].Can Med Assoc J,1976,114(10):896-897.
7Jacobson J L,Hussein M A,Barlogie B,et al.A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience[J].BrJ Haematol,2003,122(3):441-450.
8Bataille R,Durie B G,Grenier J,et al.Prognostic factors and staging in multiple myeloma:a reappraisal[J].J Clin Oncol,1986,4(1):80-87.
3Hatzimichael E, Dasoula A, 8enetatos L, et aL Study of specific genetic and epigenetic variables in multiple myeloma[J]. Leuk Lymphoma, 201 0, 51 (1 2):2270-2274.
4Rossi M, Di Martino MT, Morelli E, etal. Molecular targets for the treatment of multiple myeloma[J]. Curt Cancer Drug Targets, 2012, 12(7):757-767.
5Tassone P, Neri P, Burger R, et al. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma[J]. Curr Cancer Drug Targets, 2012, 12(7):814-822.
6Hideshima T, Anderson KC. Novel therapies in MM: from the aspect of preclinical studies[J]. Int J Hematol, 2011,94(4):344-354.
7Bird JM, Owen RG, D'Sa S, et al. Guidelines for the diagnosis and management of multiplemyeloma 2011[J]. BrJ Haematol, 2011, 154(1):32-75.
8Hasskarl J, Ihorst G, De Pasquale D, et al. Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma[J]. Leuk Lymphoma, 2011, 52(2):247-259.
9Pathak AB, Advani SH, Gopal R, et al. Urinary bladder cancer following cyclophosphamide therapy for Hodgkin's disease[J]. Leuk Lymphoma, 1992, 8(6):503-504.
10Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study[J]. Eur J Haernatol, 2000, 65(2):123-127.
